Trials / Unknown
UnknownNCT03014102
Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Hongnan Mo · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether recombinant human thrombopoietin are effective in peripheral blood progenitor cells mobilization for autologous transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Human Thrombopoietin | Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin. |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
- First posted
- 2017-01-09
- Last updated
- 2019-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03014102. Inclusion in this directory is not an endorsement.